An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus in Mice

An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus in Mice

Tick-borne encephalitis virus (TBEV) is a pathogen that causes severe human neuroinfections in Europe and Asia for which there is currently no specific therapy. The adenosine analogue galidesivir (BCX4430), a broad-spectrum RNA virus inhibitor, has entered a phase 1 clinical safety and pharmacokinet...

Full description

Bibliographic Details
Main Authors: Jan Haviernik, Ludek Eyer, Antoine Nougairède, Marie Uhlířová, Jean-Sélim Driouich, Darina Zouharová, James Jason Valdés, Ernest Gould, Erik De Clercq, Xavier de Lamballerie, Daniel Ruzek
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Proceedings
Subjects:
BCX4430
attenuation
drug resistance
galidesivir
mutation
tick-borne encephalitis virus
Online Access:https://www.mdpi.com/2504-3900/50/1/12

Internet

https://www.mdpi.com/2504-3900/50/1/12

Similar Items